UBS Group upgraded shares of Charles River Laboratories International (NYSE:CRL – Free Report) to a strong-buy rating in a research note issued to investors on Wednesday morning,Zacks reports. Other equities research analysts have also issued reports about the stock. BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in […]